Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omnicell, Inc. (NASDAQ: OMCL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As a publicly traded healthcare technology company focused on intelligent medication management, Omnicell files a range of reports with the U.S. Securities and Exchange Commission that describe its financial condition, risks, governance, and material events.
Investors and researchers can use this page to review Omnicell’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss topics such as revenues from connected devices, technical services, SaaS and Expert Services, and consumables, as well as the company’s strategy to transform into a digitally enabled medication management technology company. Current reports on Form 8-K provide timely updates on matters including quarterly financial results, amendments to bylaws, and the appointment of executive officers.
For users interested in governance and corporate structure, filings detail actions like the adoption of amended and restated bylaws that refine stockholder nomination procedures, address proxy rule requirements, and clarify jurisdictional provisions. Risk factor discussions in Omnicell’s periodic reports outline considerations related to economic conditions, demand for medication management solutions, regulatory and legal obligations, cybersecurity, supply chain, and competition.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of Omnicell’s 10-Ks, 10-Qs, and 8-Ks without reading every page. Real-time updates from EDGAR, combined with structured access to historical filings, allow investors to follow how OMCL’s disclosures evolve over time and to connect regulatory information with the company’s broader narrative in medication management technology.
Omnicell reported Q3 2025 results, with total revenue of $310.6 million, up from $282.4 million a year ago. Product revenue was $177.5 million and service revenue was $133.1 million. Net income was $5.5 million, or $0.12 per diluted share, versus $8.6 million, or $0.19, last year as operating expenses rose.
For the first nine months, revenue reached $870.9 million with net income of $4.1 million. Cash from operations was $96.9 million. The company ended the quarter with $180.1 million in cash and cash equivalents. Omnicell repaid the remaining $175.0 million principal of its 0.25% convertible notes due 2025 and had $167.3 million (net) outstanding on the 1.00% notes due 2029. Deferred revenues were $245.5 million, including $178.8 million current.
Stockholders’ equity was $1.22 billion. The company repurchased common stock totaling $77.6 million year‑to‑date, and shares outstanding were 44,876,522 as of October 29, 2025.
Omnicell, Inc. furnished an update on performance, announcing third-quarter 2025 financial results and an update to full-year 2025 guidance via a press release. The company provided the details in Exhibit 99.1, referenced under Item 2.02 of the report. The information in Item 2.02 and Exhibit 99.1 is being furnished and not filed under the Exchange Act.
Dimensional Fund Advisors LP filed a Schedule 13G reporting beneficial ownership of 2,364,068 shares of Omnicell Inc. Common Stock, representing 5.1% of the class. Dimensional states these shares are owned by mutual funds, commingled funds, group trusts and separate accounts for which it serves as investment adviser or sub-adviser, and it disclaims beneficial ownership while reporting its voting and dispositive powers: 2,303,090 shares of sole voting power and 2,364,068 shares of sole dispositive power. The filing confirms the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
Omnicell, Inc. filed an 8-K to report that its board of directors adopted the company’s Fourth Amended and Restated Bylaws, effective September 30, 2025. The updated bylaws refine how shareholders can nominate directors and submit proposals at annual and special meetings, adding more detailed disclosure requirements for nominating or proposing shareholders, their nominees, and any individuals behind entity shareholders. The revisions also address matters related to Rule 14a-19 of the Exchange Act, clarify the company’s forum and personal jurisdiction provisions for certain lawsuits, and make various ministerial and conforming changes.
Corey J. Manley, Executive Vice President & Chief Legal/Administrative Officer of Omnicell, Inc. (OMCL), reported a sale of 3,880 shares of Omnicell common stock on 09/12/2025 at a price of $33.25 per share. After the transaction, Mr. Manley beneficially owned 110,653 shares, held directly. The filing notes the sale was made pursuant to a pre-established Rule 10b5-1 trading plan adopted on June 13, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Manley on 09/16/2025.
Omnicell, Inc. (OMCL) Form 3 filed for Radford Harlan Baird, who is listed as an Officer (EVP & Chief Financial Officer) and director-level reporting person. The statement, tied to the 08/26/2025 event date, reports no securities beneficially owned by the reporting person. The filing is signed by an attorney-in-fact on 09/05/2025 and attaches a power of attorney as Exhibit 24.
Omnicell, Inc. announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer in a press release dated August 25, 2025. The filing lists the press release as Exhibit 99.1 and includes the interactive data cover page as Exhibit 104. The document is signed by Corey J. Manley, Executive Vice President and Chief Legal and Administrative Officer.
The filing provides the appointment notice but contains no additional financial figures, background detail about the appointee, effective date beyond the press release date, or commentary on transition plans or compensation.
Omnicell insider transaction: This Form 4 shows that Etta Nchacha, EVP & CFO of Omnicell, disposed of 3,532 shares of Omnicell common stock on 08/15/2025 at a reported price of $31.69 per share. The filing indicates the disposition code "F," and an explanation states the shares were withheld to cover taxes due upon the vesting of restricted stock units.
The filing also reports that Ms. Nchacha beneficially owned 125,176 shares after the transactions, with that balance adjusted to reflect the purchase of 211 shares under the company Employee Stock Purchase Plan on 08/15/2025. The Form is signed by an attorney-in-fact on 08/19/2025.
Randall A. Lipps, Chairman, President and CEO of Omnicell, Inc. (OMCL), reported an internal stock withholding transaction tied to restricted stock unit vesting. The filing shows Mr. Lipps indirectly owns 355,861 shares held in trust with his wife and 8,051 shares held in trust for his children. On 08/15/2025 he had 8,438 shares withheld to cover taxes at a price of $31.69 per share, reducing the reported beneficial ownership to 395,085 shares following the transaction. The form was signed on 08/19/2025 by an attorney-in-fact.
Corey J. Manley, EVP & Chief Legal/Administrative Officer and director of Omnicell, Inc. (OMCL), reported a sale and related ownership update on 08/15/2025. The filing shows 2,792 shares were disposed at a price of $31.69 each, recorded as withholding related to the vesting of restricted stock units to cover taxes. After the transaction and a separate purchase of 199 shares under the company ESPP on 08/15/2025, Mr. Manley beneficially owns 114,533 shares (direct). The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.